MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Metrics to compare | MDWD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMDWDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.7x | 28.3x | −0.6x | |
PEG Ratio | −0.33 | 0.29 | 0.00 | |
Price/Book | 4.8x | 2.5x | 2.6x | |
Price / LTM Sales | 11.5x | 2.2x | 3.2x | |
Upside (Analyst Target) | 70.8% | 30.2% | 41.8% | |
Fair Value Upside | Unlock | 1.1% | 5.1% | Unlock |